Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer

BACKGROUND: Numerous studies have assessed the association between xeroderma pigmentosum complementation group C (XPC) polymorphisms and susceptibility of prostate cancer (PCa); however, the findings remain inconsistent. METHODS: We performed an updated analysis utilizing data from electronic databases to obtain a more accurate estimation of the relationship between XPC rs2228001 A/C polymorphism and PCa risk. We further used in silico tools to investigate this correlation. RESULTS: Totally, 5,305 PCa cases and 6,499 control subjects were evaluated. When all studies pooled together, we detected no positive result (recessive genetic model: OR = 1.14, 95% CI = 0.93‐1.40, P (heterogeneity) = 0.001, P = .212); nevertheless, the XPC rs2228001 A/C variant was associated with PCa risk in Asian descendants in the subgroup analysis (OR = 1.21, 95% CI = 1.01‐1.43, P (heterogeneity) = 0.008, P = .034). In silico tools showed that more than 20 proteins can participate in the protein crosstalk with XPC. The expression of XPC was down‐regulated in all Gleason scores of prostate cancer. CONCLUSIONS: The present study indicated that the XPC rs2228001 A/C variant may be associated with elevated PCa risk in Asian patients.